Praxis Precision Medicine PRAX

HealthcareMarket cap $1B0 connections

Praxis develops precision medicines for neurological diseases - epilepsy, essential tremor, and depression - targeting specific ion channels in neurons. Its PRAX-628 for epilepsy and PRAX-944 for essential tremor show promising early clinical results. Ion channel precision medicine could replace broad-acting psychiatric drugs with targeted neurology.

Explore Praxis Precision Medicine on the interactive map Relationship timeline Find a path to another company

We haven't documented any relationships for this company yet.

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Praxis Precision Medicine's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=PRAX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Praxis Precision Medicine on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.